Literature DB >> 18265414

Validating the effects of drug treatment on blood pressure in the General Practice Research Database.

Joseph A C Delaney1, Erica E M Moodie, Samy Suissa.   

Abstract

PURPOSE: Observational studies using clinical databases, such as the United Kingdom's General Practice Research Database (GPRD), may provide an alternative to clinical trial data for detecting longitudinal changes in blood pressure due to drug exposures that vary over time. Blood pressure data which are measured at variable intervals and are often missing present a particular methodological challenge to the analysis of such studies.
METHODS: To assess effects on blood pressure, we extracted from the GPRD several cohorts of new drug users of warfarin (n = 21,532), ibuprofen (n = 92,037), proton pump inhibitors (n = 153,695), statins (n = 118,704), rofecoxib (n = 6399), and celecoxib (n = 6217) from 2001 to 2003. Several blood pressure readings were missing either before or after initiating therapy. We compared the results of analyses using a linear mixed model with a pre-post quasi-experimental design, using the multiple imputation approach to account for missing data.
RESULTS: There was evidence that the missing blood pressure data were not missing completely at random as subjects with more blood pressure readings tended to have higher recorded values. For statins, the mixed model estimated a change in systolic blood pressure of -3.80 mmHg (99% confidence interval (CI): from -3.97 to -3.63), similar to the quasi- experimental model and to the -4.00 mmHg estimated from clinical trials. Sensitivity analyses indicate that these estimates are robust. For rofecoxib, the change in systolic blood pressure were 2.20 mmHg (99%CI: 1.09-3.32) and 1.21 mmHg (99%CI: 0.21-2.22) for the two methods, respectively, again confirming the findings of randomized trials.
CONCLUSION: With appropriate statistical techniques, GPRD blood pressure data can be used to estimate blood pressure changes secondary to drug therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18265414     DOI: 10.1002/pds.1553

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  10 in total

1.  The positivity assumption and marginal structural models: the example of warfarin use and risk of bleeding.

Authors:  Robert William Platt; Joseph Austin Christopher Delaney; Samy Suissa
Journal:  Eur J Epidemiol       Date:  2011-12-08       Impact factor: 8.082

2.  Demographic, medical, and behavioral characteristics associated with over the counter non-steroidal anti-inflammatory drug use in a population-based cohort: results from the Multi-Ethnic Study of Atherosclerosis.

Authors:  Joseph A C Delaney; Mary L Biggs; Richard A Kronmal; Bruce M Psaty
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-11       Impact factor: 2.890

3.  Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV.

Authors:  Joseph A Delaney; Robin M Nance; Bridget M Whitney; Frederick L Altice; Xinyuan Dong; Maria Esther Perez Trejo; Mika Matsuzaki; Faye S Taxman; Geetanjali Chander; Irene Kuo; Rob Fredericksen; Lauren N Strand; Joseph J Eron; Elvin Geng; Mari M Kitahata; William C Mathews; Kenneth Mayer; Richard D Moore; Michael S Saag; Sandra Springer; Redonna Chandler; Shoshana Kahana; Heidi M Crane
Journal:  J Acquir Immune Defic Syndr       Date:  2018-11-01       Impact factor: 3.731

4.  Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis.

Authors:  Sandra Dial; Sharon J Nessim; Abbas Kezouh; Jacques Benisty; Samy Suissa
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

5.  Testing bias in clinical databases: methodological considerations.

Authors:  Karin J Velthove; Hubert Gm Leufkens; Patrick C Souverein; René C Schweizer; Wouter W van Solinge
Journal:  Emerg Themes Epidemiol       Date:  2010-05-14

6.  Baseline depressive symptoms are not associated with clinically important levels of incident hypertension during two years of follow-up: the multi-ethnic study of atherosclerosis.

Authors:  Joseph A C Delaney; Bruce E Oddson; Holly Kramer; Steven Shea; Bruce M Psaty; Robyn L McClelland
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

7.  Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.

Authors:  Monica A Muñoz; Wei Liu; Joseph A C Delaney; Elizabeth Brown; Michael J Mugavero; W Chris Mathews; Sonia Napravnik; James H Willig; Joseph J Eron; Peter W Hunt; James O Kahn; Michael S Saag; Mari M Kitahata; Heidi M Crane
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

8.  Ethnic differences in the progression of chronic kidney disease and risk of death in a UK diabetic population: an observational cohort study.

Authors:  Rohini Mathur; Gavin Dreyer; Magdi M Yaqoob; Sally A Hull
Journal:  BMJ Open       Date:  2018-03-27       Impact factor: 2.692

9.  Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: A propensity score-matched cohort study in the UK Clinical Practice Research Datalink.

Authors:  Karine Marinier; Pauline Macouillard; Martine de Champvallins; Nicolas Deltour; Neil Poulter; Giuseppe Mancia
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-09-03       Impact factor: 2.890

10.  Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the Cardiovascular Health Study and the Framingham Heart Study.

Authors:  Joseph Ac Delaney; Xiaoyan Yin; João Daniel Fontes; Erin R Wallace; Asheley Skinner; Na Wang; Bradley G Hammill; Emelia J Benjamin; Lesley H Curtis; Susan R Heckbert
Journal:  SAGE Open Med       Date:  2018-02-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.